Managing Bias Amplification Risks in Advanced Analytics with AI and Machine Learning for FDA Submissions In recent years, the integration of advanced analytics, artificial intelligence (AI), and machine learning (ML) into real-world data (RWD) analysis has transformed how pharmaceutical and medical technology companies conduct study designs, healthcare outcomes research, and regulatory submissions. However, this shift carries significant challenges, including the risk of bias amplification. This tutorial serves as a comprehensive guide for regulatory, biostatistics, Health Economics and Outcomes Research (HEOR), and RWD data standards professionals seeking to understand and mitigate these risks when applying AI technologies in FDA submissions. 1….

Governance for Responsible AI Use in RWE Pipelines and Submissions The integration of advanced analytics, artificial intelligence (AI), and machine learning (ML) into real-world evidence (RWE) pipelines has become increasingly significant in regulatory submissions to the US FDA. As regulatory expectations evolve, professionals in the pharmaceutical and medtech sectors must be equipped with a solid understanding of AI governance to ensure compliance with various regulatory standards. In this step-by-step tutorial, we will explore best practices, considerations, and frameworks for the responsible use of AI and analytics within RWE submissions, providing a comprehensive overview for regulatory, biostatistics, Health Economics and Outcomes…

Validation Expectations When Using ML Models in RWE Analyses Real-World Evidence (RWE) has become increasingly significant in the regulatory landscape, particularly for the validation of advanced analytics involving machine learning (ML) in FDA submissions. As regulatory expectations evolve, it is critical for professionals in the fields of regulatory affairs, biostatistics, and health economics and outcomes research (HEOR) to ensure compliance with rigorous standards. This article provides a comprehensive step-by-step regulatory tutorial on validation expectations when employing ML models in RWE analyses, with a primary emphasis on submissions to the U.S. FDA. Overview of Real-World Evidence and Regulatory Context RWE is…

Future Opportunities for Real Time, AI Driven RWE to Support Lifecycle Decisions Introduction to Real World Evidence (RWE) and FDA Submissions Real World Evidence (RWE) pertains to the clinical evidence derived from the analysis of Real World Data (RWD) related to patient health status and the delivery of health care. It encompasses health care data collected outside the confines of traditional clinical trials, often using advanced analytics, artificial intelligence (AI), and machine learning (ML). RWE is becoming increasingly important in supporting lifecycle decisions for pharmaceuticals and medical devices, particularly in regulatory submissions to the FDA. The FDA recognizes the potential…

Global Perspectives on AI in RWE Across Regulators and HTA Agencies In recent years, the landscape of drug development and regulation has shifted significantly, driven by advancements in technology, particularly in the realms of advanced analytics, AI, and machine learning (ML). Regulators, Health Technology Assessment (HTA) agencies, and industry stakeholders are exploring how these technologies can enhance real-world evidence (RWE) generation and utilization, especially in the context of regulatory submissions. This article aims to provide a comprehensive overview of the current state of AI in RWE practices across different regulatory environments, focusing on FDA perspectives and comparing them with the…

Engaging FDA Early When AI Methods Drive Key RWE Insights In the accelerating realm of healthcare analytics, Real-World Evidence (RWE) has emerged as a pivotal asset for regulatory submissions and decision-making processes. As regulatory frameworks evolve, especially under the purview of the US FDA, early engagement with agencies becomes essential for leveraging advanced analytics and Artificial Intelligence (AI) methodologies in RWE generation. This tutorial provides a comprehensive, step-by-step guide tailored for regulatory professionals, biostatisticians, and data standards experts engaged in employing advanced analytics AI machine learning RWE FDA submissions. Understanding Real-World Evidence and Its Importance Real-World Evidence (RWE) refers to…

Training RWE and Biostat Teams on ML Concepts Relevant to Regulators As the pharmaceutical and medtech industries evolve, regulatory expectations are adapting to accommodate advancements in technology, especially in the realm of advanced analytics, artificial intelligence (AI), and machine learning (ML). Training real-world evidence (RWE) and biostatistics teams on these concepts is crucial for ensuring compliance with US FDA submissions and guidance. This article serves as an extensive tutorial for regulatory, biostatistics, health economics and outcomes research (HEOR), RWE, and data standards professionals. We will cover the intersection of ML and regulation, focusing on key principles needed to lead teams…

End to End Architecture for Scalable AI-Powered RWE Analytics Platforms Introduction In recent years, the integration of advanced analytics, artificial intelligence (AI), and machine learning (ML) into the field of real-world evidence (RWE) has transformed the landscape of regulatory submissions. The U.S. FDA is increasingly recognizing the potential of these technologies to provide valuable insights into drug development, patient outcomes, and healthcare practices. As such, pharmaceutical and biotechnology companies, along with medical technology firms, are investing in scalable AI-powered RWE analytics platforms to strengthen their submission packages. This article serves as a comprehensive guide to understanding the architecture necessary for…

Data Standards for Real World Evidence: CDISC, SDTM, ADaM, and HL7 FHIR This comprehensive tutorial provides an in-depth exploration of the data standards essential for real-world evidence (RWE) within the pharmaceutical and medtech industries. We will focus on the Clinical Data Interchange Standards Consortium (CDISC) standards, specifically the Study Data Tabulation Model (SDTM) and Analysis Data Model (ADaM), and examine the integration of Fast Healthcare Interoperability Resources (FHIR). Professionals involved in regulatory compliance, biostatistics, health economics and outcomes research (HEOR), and data standards will find this guide valuable for aligning processes with US FDA expectations. The comparisons to regulatory frameworks…

Future trends in FDA thinking on pragmatic trials, RWE and hybrid designs Future Trends in FDA Thinking on Pragmatic Trials, RWE and Hybrid Designs The landscape of regulatory science is continually evolving, particularly with the growing emphasis on real-world evidence (RWE) and pragmatic trial designs. The U.S. Food and Drug Administration (FDA) has been at the forefront of integrating these methodologies into the regulatory framework for drug and device approvals. This article outlines the critical concepts within the FDA framework for RWE approvals, focusing on pragmatic trials, the totality of evidence, and future trends in regulatory decision-making. Understanding the FDA…